 |
|
|
| |
International HIV and Hepatitis Drug Resistance Workshop
Dubrovnik Croatia
June 8-12, 2010 |
| |
| |
- Clinical, Virological, and Immunological Characteristics of Patients With Discordant Phenotypic and Genotypic (Ultra-Deep Sequencing) Tropism Test Results: Analysis of Tropism Calls in MOTIVATE and 1029 - poster - (06/18/10)
- Analysis of the HIV-1 gp120 V3 Loop at Screening for Treatment-Experienced Patients in the MOTIVATE Studies With CCR5-Tropic Virologic Failure - poster - (06/18/10)
- Genotypic Analysis of V3 in Patients Experiencing Virologic Failure on Maraviroc-containing Regimens and Correlation with Pre-treatment "Deep" Sequencing Results - poster - (06/18/10)
- Long-Term Outcome of Individuals Experiencing a Phenotypic Switch in HIV-1 Co-receptor Use in the Merit Study - (06/18/10)
- Intl Resistance Workshop Report
by Mark Wainberg, PhD, McGill University, Montreal - (06/16/10)
- Strong Inhibition of Wild-Type and Integrase Inhibitor (INI)-Resistant HIV Integrase (IN) Strand Transfer Reaction by the Novel INI S/GSK1349572 - (06/15/10)
- Strong Inhibition of Wild-type and Integrase Inhibitor (INI)-Resistant HIV Integrase (IN) Strand Transfer Reaction by the Novel INI S/GSK1349572, poster report: "S/GSK1349572 had stronger and faster binding to mutant IN than RAL" - (06/15/10)
- S/GSK1349572 Demonstrates Significantly Slower Dissociation Rates than Raltegravir when Comparing Wild Type and Raltegravir Resistant Integrase Protein - (06/15/10)
- HIV Integrase Resistance Profiles and S/GSK1349572 Baseline Phenotypic Susceptibility for Subjects Experiencing Virologic Failure on Raltegravir (RAL) in the VIKING Study (ING112961) - (06/15/10)
- S/GSK1349572 Demonstrates Significantly Slower Dissociation Rates than Raltegravir When Comparing Wild Type and Raltegravir Resistant Integrase Protein - (06/15/10)
- Structural Models of HIV-1 Integrase and DNA in Complex with S/GSK1349572, Raltegravir and Elvitegravir: Structure-based Rationale for INI Resistance Profiles - (06/15/10)
- Deep sequencing analysis of baseline and on-treatment samples from HCV genotype-1 patients treated for 5 days with TMC435 monotherapy and subsequently re-treated with TMC435 in combination with PegIFNα-2a/ribavirin - poster presentation - (06/14/10)
- Samples from HCV Genotype-1 Patients Treated for 5 Days with TMC435 Monotherapy and Subsequently Re-treated with TMC435 in Combination with PegIFNα-2a/Ribavirin - slide talk - (06/14/10)
- Analysis of Resistance in Virologic Failures during IFN/RBV Therapy Post 28-Day Treatment with MK7009: Results through Week 24 of the Phase 2A Dosing Finding Study in Genotype 1 Patients - (06/12/10)
- Long-term Follow-up of Patients Treated with Boceprevir in Combination with PEG-Intron/Ribavirin (P/R): Durability of Responses and Rates of Reversion of Resistance Mutations - (06/12/10)
- Only Two Major PI Mutations (But No Resistance) in Darunavir Monotherapy Trial - written by Mark Mascolini - (06/12/10)
- US/Canadian HIV Transmission Clusters Largely Male, White, and Gay - written by Mark Mascolini - (06/12/10)
- Infection With 3TC/FTC Mutant Virus Favors Lower Pretreatment Viral Load - written by Mark Mascolini - (06/12/10)
- Treatment Success Rates High, Resistance Rates Lower, in France in 2009, but integrase resistance is present among failures - written by Mark Mascolini - (06/12/10)
- HIV CSF/Plasma Ratio and Genetic Distance in People With Neurologic Disorders - written by Mark Mascolini - (06/12/10)
- Genotypic Analysis of V3 in Patients Experiencing Virologic Failure on Maraviroc-containing Regimens and Correlation with Pre-treatment Deep Sequencing Results - (06/11/10)
- Clinical, Virological, and Immunological Characteristics of Patients With Discordant Phenotypic and Genotypic (Ultra-Deep Sequencing) Tropism Test Results: Analysis of Tropism Calls in MOTIVATE and 1029 - (06/11/10)
- Use of the Enhanced Sensitivity Tropism Assay (ESTA) to Predict On-Treatment Detection of CXCR4-using Virus and Impact on Virologic Outcomes in a Vicriviroc (VCV) Phase 2 Treatment Experienced Study (VICTOR-E1) - (06/11/10)
- Mutation Rate in Antiretroviral-Naive Falling in One US Patient
Population (GSK studies in USA) - written by Mark Mascolini - (06/11/10)
- Are Single Transmitted Mutants the Tip of a Resistance Iceberg? - written by Mark Mascolini - (06/11/10)
- New Mutations Found in 43% of People With Low But Detectable Viral Loads - written by Mark Mascolini - (06/11/10)
- Study Clarifies Risk of Switch to Raltegravir From Suppressive PI - written by Mark Mascolini - (06/11/10)
- Truvada Protects Macaques From Rectal Exposure to FTC-Resistant Virus - written by Mark Mascolini - (06/11/10)
- Transmitted Resistance Imperils First-Line Response in 10,000-Person Study - written by Mark Mascolini - (06/11/10)
- "Deep" Sequencing Finds X4 Virus in Screening Samples of Maraviroc Failures - written by Mark Mascolini - (06/10/10)
- Pairwise Comparison of genotypic tropism prediction between one reference center and 10 European laboratories - (06/10/10)
- Better Etravirine Response Predicted After Efavirenz Than Nevirapine - written by Mark Mascolini - (06/10/10)
- Over Half of European Raltegravir Failures Without
Apparent Integrase Mutations - written by Mark Mascolini - (06/10/10)
- GSK Integrase Following Raltergavir Use: When Is It Risky to Use S/GSK1349572 After Raltegravir? - written by Mark Mascolini - (06/10/10)
- Debate Follows Data on Genotypic Predictions of HIV Tropism - written by Mark Mascolini - (06/10/10)
- Resistance Emergence With Raltegravir Versus Efavirenz in Treatment Naive - written by Mark Mascolini - (06/10/10)
- Temporal Order of Resistance Emergence for Lamivudine/Emtricitabine, Efavirenz, and Raltegravir in Treatment-Naïve Patients - (06/10/10)
- Differing Integrase Dissociation Rates With S/GSK1349572 and Raltegravir - written by Mark Mascolini - (06/10/10)
|
|
| |
|
|
|
|
|
|
